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and total ROS to promote survival and
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Hypoxia-inducible gene domain family member 1A
(HIGD1A) is a survival factor induced by hypoxia-
inducible factor 1 (HIF-1). HIF-1 regulates many re-
sponses to oxygendeprivation, but viable cells within
hypoxic perinecrotic solid tumor regions frequently
lackHIF-1a. HIGD1A is induced in theseHIF-deficient
extreme environments and interacts with the mito-
chondrial electron transport chain to repress oxygen
consumption, enhance AMPK activity, and lower
cellular ROS levels. Importantly, HIGD1A decreases
tumorgrowthbutpromotes tumor cell survival in vivo.
The human Higd1a gene is located on chromosome
3p22.1, where many tumor suppressor genes reside.
Consistent with this, the Higd1a gene promoter is
differentially methylated in human cancers, prevent-
ing its hypoxic induction. However, when hypoxic tu-
mor cells are confronted with glucose deprivation,
DNA methyltransferase activity is inhibited, enabling
HIGD1A expression, metabolic adaptation, and pos-
sible dormancy induction. Our findings therefore re-
veal important new roles for this family of mitochon-
drial proteins in cancer biology.
INTRODUCTION
Heart disease, stroke, and cancer are associated with hypoxia
(Semenza, 2014) and nutrient deprivation (Hardie et al., 2012).
Hypoxia inducible factor 1 (HIF-1) is a widely expressed tran-
scription factor that regulates the survival of cells during oxygen
and glucose deprivation (Iyer et al., 1998; Maltepe et al., 1997;CeOchiai et al., 2011; Ryan et al., 1998). HIF can also regulate tumor
metabolism by repressing respiration (Kim et al., 2006; Papan-
dreou et al., 2006) while promoting glycolysis, which enables
rapid tumor cell proliferation (Vander Heiden et al., 2009).
When severe, cancer cells can survive hypoxia and/or nutrient
deprivation by entering a dormant state, which suppresses their
growth (Bragado et al., 2012; Sosa et al., 2013). Since most can-
cer therapies target proliferating cells, oxygen/nutrient-deprived
tumor regions frequently become resistant and contribute to
tumor recurrence. New agents are therefore being developed
to target these regions (Harada et al., 2012; Zhang et al.,
2014). Paradoxically, chronically oxygen-starved tumor regions
frequently lack HIF-1a expression (Ameri et al., 2010; Sobhanifar
et al., 2005), likely due to simultaneous glucose deprivation (Ca-
trina et al., 2004; Osada-Oka et al., 2010). However, some HIF-1
target genes such as CAIX remain either due to greater protein
stability (Sobhanifar et al., 2005) or HIF-1-independent pathways
(van den Beucken et al., 2009).
Oxygen or glucose deprivation promotes reactive oxygen spe-
cies (ROS) production, which can trigger adaptive responses
such as HIF induction (Sena and Chandel, 2012) or can induce
apoptosis (Malhotra et al., 2008). Therefore, cells need to modu-
late both oxygen consumption and ROS production in order to
survive oxygen/glucose deprivation. One pathway that cells uti-
lize to achieve this relies on AMP-dependent protein kinase
(AMPK) activation (Jeon et al., 2012). AMPK can activatemultiple
adaptive pathways, including antioxidant mechanisms. Interest-
ingly, the effects of AMPK on tumor growth are complex, acting
as oncogene or tumor suppressor depending on context (Hardie
and Alessi, 2013).
Hypoxia-Inducible Gene Domain Family Member 1A (HIGD1A)
is a survival factor regulated by HIF-1 (Wang et al., 2006). We
previously demonstrated that HIGD1A is expressed in regions
of severe ischemia in vivo (Ameri et al., 2013) that frequentlyll Reports 10, 891–899, February 17, 2015 ª2015 The Authors 891
Figure 1. HIGD1A Protects against Glucose
Starvation and Suppresses Tumor Growth
with Diminished Apoptosis
(A) (i) Immunoblot analysis of HIGD1A levels
following small hairpin RNA (shRNA)-mediated
knockdown in WT MEFs (control shRNA = ctrl). (ii
and iii) Phase-contrast microscopy and trypan
blue exclusion count indicate that HIGD1A is
necessary for survival of cells during glucose
starvation/hypoxia. 20,000 cells were seeded in
6-well plates and counted after 4 days.
(B) (i) Immunoblot analysis comparing protein
levels of HIGD1A in HIF-deficient (Hif-1a/) MEFs
stably expressing HIGD1A versus wild-type MEFs
(Hif-1a+/+) exposed to hypoxia. (ii) Colony forma-
tion assays showing that HIGD1A expression in
HIF-deficient (Hif-1a/) MEFs results in fewer as
well as smaller colonies during combined hypoxia/
glucose deprivation or glucose deprivation alone.
(C) Viability assay of Hif-1a/ MEFs expressing
HIGD1A compared with control GFP cells
following 3 days of glucose deprivation.
(D) Hif-1a / MEFs stably expressing HIGD1A
resulted in significantly smaller tumor xenografts
when grown for 3 weeks subcutaneously in mice.
(E) (i) Histopathological analysis indicating lack
of necrosis in Hif-1a/ HIGD1A tumors but
profound necrosis in Hif-1a / GFP control tu-
mors. Cleaved-caspase-3 immunohistochemical
staining shows significantly more apoptosis in
Hif-1a/ GFP control tumors (ii).
Error bars represent ± SD. *p < 0.05. Five mice
per group were used for tumor growth and
analysis.lack detectable HIF-1 activity. To investigate this phenomenon,
we interrogated the function of HIGD1A in RAS-transformed
HIF-1-deficient MEFs (Ryan et al., 2000) as well as in human can-
cers in vitro and in vivo. Our studies identify novel functions for
HIGD1A with implications for tumor cell survival and dormancy
mechanisms.
RESULTS
HIGD1A Protects from Oxygen and Glucose Deprivation
but Suppresses Growth
HIGD1A can protect cells from glucose- and oxygen-depriva-
tion-induced death (Wang et al., 2006). To confirm this, we
generated HIGD1A ‘‘knockdown’’ mouse embryonic fibroblasts
(MEFs) (Figure 1Ai), which exhibited poor survival during oxy-
gen/glucose deprivation (Figures 1Aii and 1Aiii). To isolate the
function of this single HIF-1a target from other HIF-dependent892 Cell Reports 10, 891–899, February 17, 2015 ª2015 The Authorseffects, we generated HIF-1a-deficient
MEFs (Hif-1a/ MEFs) that stably ex-
pressed HIGD1A to levels observed in
wild-type MEFs exposed to hypoxia (Fig-
ure 1Bi). Sustained HIGD1A expression in
Hif-1a/ MEFs had negligible effects on
colony formation under normoxic or hyp-
oxic conditions (Figure 1Bii). Glucosedeprivation reduced colony size and number in Hif-1a /
MEFs expressing either HIGD1A or GFP (Figure 1Bii). However,
Hif-1a / MEFs expressing HIGD1A produced even fewer
numbers of colonies that were also smaller in size during
glucose- or combined glucose/oxygen deprivation (Figure 1Bii).
Interestingly, HIGD1A expression protected Hif-1a/ MEFs
from death during glucose deprivation (Figure 1C), suggesting
that increased cell death was not the cause for reduced colony
number or size. Consistent with these results, tumors derived
from Hif-1a/ MEFs expressing HIGD1A were much smaller
than control Hif-1a/ MEF tumors (Figure 1D) and did not
contain any appreciable areas of necrosis, which was widely
seen in control tumors (Figure 1Ei). Furthermore, these tumors
also exhibited significantly less apoptosis (Figure 1Eii). These
results indicate that HIGD1A can promote cell survival during
nutrient deprivation while simultaneously suppressing growth
in vitro and in vivo.
Figure 2. HIGD1A Can Regulate Mitochon-
drial Superoxide and Oxygen Consumption
during Glucose Starvation
(A) Immunoprecipitation assay showing HIGD1A
can interact with complex III subunit 2 of the res-
piratory chain.
(B) FACS analysis showing that HIF-deficient
cells expressing HIGD1A have increased mito-
chondrial ROS (superoxide) during glucose star-
vation compared to control cells expressing GFP.
(Ci and Cii) Oxygen consumption is lower during
glucose deprivation when HIGD1A is expressed in
Hif-1a/ cells.
(Di and Dii) When glucose is re-introduced to
glucose-starved cells, HIGD1A-expressing cells
increase their oxygen consumption at a faster rate
than control GFP-expressing cells.
Error bars represent ±SD, *p < 0.05.HIGD1A Interaction with the Electron Transport Chain
Modulates Mitochondrial ROS Production and Oxygen
Consumption
HIGD1A is an inner mitochondrial protein, and recently orthologs
of HIGD1A and the related HIGD2A were shown to interact with
complex IV in yeast (Chen et al., 2012; Strogolova et al., 2012).
Immunoprecipitation assays with extracts derived from MEFs
expressing GFP-tagged HIGD1A detected an interaction be-
tweenmurine HIGD1A and complex III subunit 2 of themitochon-
drial electron transport chain (ETC), but not with complex IV
subunit I (Figure 2A). Complex III is an important site for mito-
chondrial superoxide (O2
) production (Buetler et al., 2004;
Chen and Gibson, 2008), which can be increased when the
proton motive force increases, as occurs with decreased flow
through the respiratory chain (Murphy, 2009). Therefore, we
examined the level of mitochondrial O2
 production via fluores-
cence-activated cell sorting (FACS)-mediated analysis of Mito-
sox Red intensity. This was increased to a greater extent in
HIGD1A-expressing Hif-1a/ MEFs during glucose starvation
than their GFP-expressing counterparts (Figure 2B). Addition-
ally, HIGD1A expression in Hif-1a/ MEFs resulted in an
approximately 2-fold reduction in cellular oxygen consumption
during glucose deprivation (Figures 2Ci and 2Cii). Interest-
ingly, following re-introduction of glucose, oxygen consumptionCell Reports 10, 891–899,was reversed more rapidly in cells stably
expressing HIGD1A (Figures 2Di and
2Dii). These results indicate that HIGD1A
expression can modulate mitochondrial
ROS production and oxygen consump-
tion during conditions of glucose depriva-
tion via interaction with the ETC.
HIGD1A Induces AMPK Activity and
Decreases Cellular ROS to Promote
Survival
ROS generation during glucose depriva-
tion can result in cell death (Gao et al.,
2012; Lenin et al., 2012; Malhotra et al.,
2008). AMPK can be induced by glucosedeprivation and mitochondrial O2
 production (Wu and Wei,
2012; Mackenzie et al., 2013) to reduce total ROS via the promo-
tion of pentose phosphate shunt-mediated NADPH production
(Jeon et al., 2012). Consistent with these studies, Hif-1a/
MEFs that stably expressed HIGD1A increased pAMPK levels
to a greater extent than control cells during glucose deprivation
(Figure S1A), and this effect was reduced by the mitochondria-
targeted antioxidant MitoQ (Kelso et al., 2001) (Figure S1B).
Furthermore, this diminished total cellular ROS in HIGD1A-ex-
pressing cells during glucose starvation (Figure S1C), and a
cell permeable form of the antioxidant glutathione (Graham
et al., 2012) improved the viability of controlHif-1a/MEFs dur-
ing glucose deprivation (Figure S1D). Thus, HIGD1A triggers
increased mitochondrial O2
 production to activate AMPK and
decrease total cellular ROS levels to promote cell survival. To
determine whether AMPK activity was necessary for the protec-
tive effect of HIGD1A during glucose deprivation, we stably
transfected Ampk1/2/ MEFs with HIGD1A or GFP as control
and examined their survival during glucose starvation. AMPK-
deficient cells do not reduce total cellular ROS levels and fail
to induce autophagy during glucose starvation, compromising
their survival (Jeon et al., 2012; Kim et al., 2011). Interestingly,
HIGD1A expression did not protect Ampk1/2/ MEFs from
glucose starvation (Figure S1E), indicating that AMPK activationFebruary 17, 2015 ª2015 The Authors 893
is necessary for the protective effect of HIGD1A during glucose
deprivation. We also examined AMPK activation in vivo utilizing
tumors derived from Hif-1a/ MEFs expressing HIGD1A previ-
ously described in Figure 1D and found that they demonstrated
pAMPK immunoreactivity that was more intense as well as more
diffusely distributed than control tumors (Figure S1F), consistent
with the reduction of cell death. Immunoreactivity of pAMPKwas
ablatedwhen treatedwith pAMPKblocking peptide (Figure S1G).
Finally, we questioned whether the effects of HIGD1A-depen-
dent pAMPK induction during glucose deprivation could be
due to autophagy induction, since it can also be regulated by
AMPK to increase cell survival during glucose starvation (Kim
et al., 2011). As seen in Figure S2, autophagy induction was
dispensable for the protective effects of HIGD1A.
HIGD1A Is Not Induced by HIF-1a in Hypoxic Human
Cancers but Is Triggered by Additional Metabolic
Stressors
We next examined the mode of regulation of HIGD1A in a variety
of human cancer cell lines. Human HT1080 fibrosarcoma and
HeLa cervical cancer cell lines exhibited basal levels of HIGD1A
that were surprisingly not further induced by hypoxia, despite
inducing HIF-1a (Figure 3A). BNIP3, another HIF-1 target mito-
chondrial protein (Sowter et al., 2001), was induced, however.
The gene encoding HIGD1A is located on human chromosome
3p22.1, where many tumor suppressor genes reside, and these
are often inactivated via epigenetic mechanisms (Bhat Singh and
Amare Kadam, 2013; Buchhagen et al., 1994). From genome-
wide analyses of aberrant DNA methylation in glioblastoma
multiforme (GBM) (Nagarajan et al., 2014), we identified two
candidate regions near the Higd1a promoter that exhibited
GBM-specific hypermethylation. As indicated in Figure 3B, one
of these regions, located upstream of the 50 CpG island pro-
moter, in a CpG island ‘‘shore,’’ contains consensus core hypox-
ia response elements (HREs; blue underline). Two CpG sites
within this region are interrogated on the Illumina HumanMethy-
lation450 methylation array and exhibit high methylation in
several cancer cells and only partial methylation in normal hu-
man NH-A astrocytes (ENCODE data), indicating that it may be
a differentially methylated region (DMR, red and green CG).
Chromatin immunoprecipitation sequencing (ChIP-seq) profiles
from the Roadmap Epigenomics Project confirmed the presence
of histone modifications associated with enhancers in both brain
and breast, consistent with it harboring potential HREs. ChIP
analysis confirmed that HIF-1a was able to bind the HRE within
this DMR in HeLa cells during hypoxia (Figure 3C), despite its
expression not being induced. Treating HeLa cells with the
DNA methylation inhibitor 5-aza-20-deoxycytidine, however,
enhanced HIGD1A expression during hypoxia (Figure 3D).
Reduced expression of DNA methyl transferase 1 (DNMT1) can
reactivate tumor suppressors (Xiang et al., 2014; Yao et al.,
2014), and glucose starvation can reduce expression of the
gene encoding DNMT1 (Lin et al., 2012). Glucose starvation
reduced DNMT1 expression in hypoxic HeLa cells suggesting
that DNA methylation pathways are inhibited during combined
oxygen/glucose deprivation (Figure 3E). Reduction of DNMT1
correlated with enhanced HIGD1A expression during glucose
starvation (Figure 3F). Unlike canonical tumor suppressor genes894 Cell Reports 10, 891–899, February 17, 2015 ª2015 The Authorsthat are sometimes strongly and permanently silenced by dense
methylation across their promoter CpG islands, the Higd1a gene
locus shows more nuanced epigenetic regulation in human can-
cer. DNA methylation at upstream HREs might prevent transac-
tivation of HIGD1A via HIF-1 and thereby suppress enhanced
HIGD1A expression during growth permissive hypoxic condi-
tions but allow epigenetic activation when environmental condi-
tions favoring HIGD1A expression are encountered.
HIGD1A Expression Is Enhanced in Severely Ischemic
Tumor Regions In Vivo
We next examined whether HIGD1A expression is induced in a
similar fashion in human cancers in vivo, particularly since
reduced methyl cytosine levels have been reported in ischemic
tumor regions due to reduced DNMT activity (Shahrzad et al.,
2007; Skowronski et al., 2010). MDA-MB 231 breast cancer xe-
nografts demonstrated severely ischemic perinecrotic regions
as evidenced by strong staining with the hypoxia marker pimodi-
nazole, along with diminished HIF-1a immunoreactivity, indi-
cating likely glucose starvation (Figure 4A). As shown in Fig-
ure S3, lack of HIF-1a was also observed in severely ischemic
myocardial regions following experimental myocardial infarction
in mice, suggesting that this may be a common indicator of star-
vation severity. As indicated in Figures 4B and S3, these areas of
ischemia demonstrated enhanced HIGD1A expression. Similar
to our observations with HeLa cells, DNMT1 levels were also
reduced in ischemic MDA-MB 231 cells (Figure 4C). In addition,
HIGD1A expression was enhanced in vitro in ischemic MDA-MB
231 cells when compared with hypoxia (Figure 4D). Circulating
tumor cells (CTCs) derived from MDA-MB 231 xenografts were
previously reported to be more resistant to anoxia (Ameri et al.,
2010). Both MDA-MB231 cells and their CTCs induced HIF-1a
but not HIGD1A during hypoxia (Figure 4E). Interestingly, basal
levels of HIGD1A were higher in CTCs. These results further
confirm that hypoxic HIF-1a induction is not sufficient to
enhance HIGD1A expression in human cancers in vitro or in vivo,
but that additional pathways triggered by severe metabolic
stressors are necessary. Finally, we analyzed HIGD1A expres-
sion patterns in glioblastoma multiforme (GBM) biopsies from
patients before and after treatment with the anti-angiogenesis
agent bevacizumab, which is known to induce severe tumor
ischemia (Hu et al., 2012). Primary GBM biopsies exhibited hyp-
oxic areas as evident by increased CA9 expression (Figure 4F).
These areas did not demonstrate significant HIGD1A expres-
sion. However, after treatment with bevacizumab, HIGD1A
was strongly induced (Figure 4F). This indicates that HIGD1A
expression is prevented during physiological hypoxia and that
additional metabolic stressors are needed to induce HIGD1A in
human cancers in vivo.
DISCUSSION
We and others previously documented (Ameri et al., 2010; Sob-
hanifar et al., 2005) and confirmed once again here that some
of the most metabolically compromised tumor regions found
around their necrotic cores fail to induce HIF activity, potentially
due to glucose starvation (Catrina et al., 2004; Osada-Oka et al.,
2010). Interestingly, these regions still express the HIF-1 target
Figure 3. Expression and Regulation of HIGD1A in Cancer
(A) Immunoblot analysis of HIGD1A, HIF-1a, and BNIP3 expression in human HT1080 and HeLa cancer cell lines during normoxia or hypoxia.
(B) Data from Illumina HumanMethylation450 methylation array, and the ENCODE consortium showing high methylation level (vertical orange lines) upstream of
the 50 CpG island promoter, in a CpG island ‘‘shore.’’ The HIGD1ACpG island itself is generally unmethylated (vertical blue and violet lines) in both cancer cell lines
(U87, ovcar-3, HCT-116, HeLa) as well as in normal human astrocytes (NH-A). Two of the CpGs (within vertical gray rectangle) in the 50 shore of that CpG island
have high methylation levels in HeLa, ovcar-3, HCT-116, and U87 cell lines and partial methylation in normal human astrocytes, indicating a potential differential
methylated region (DMR, red, and green CG in the sequence given). The sequence of the entire 50 region (region chromosome 3: 42846997-42847502) including
the two specific CpGs (highlighted as green and red in the sequence) of this putative DMR neighbors several HRE-core sequences (blue underlined). ChIP-seq
data from the Roadmap Epigenomics Project indicate that this region is marked by histone modifications associated with enhancers (yellow and orange bars) in
both brain (FB ChromHMM, BGM ChromHMM) and breast (BMC ChromHMM). Primers used for CHIP analysis in black underlined.
(C) ChIP analysis performed on normoxic (N) or hypoxic (H) HeLa cells using primers (black underlined in sequence) within the 50 region that contains the two
specific CpGs (highlighted as green and red in the sequence) of this putative DMR.
(D) Immunoblot analysis demonstrating expression of HIGD1A protein in the human cervical cancer cell line HeLa in hypoxia (H) versus hypoxia combinedwith the
DNA methylation inhibitor (DNMT-inhibitor) 5-aza-20-deoxycytidine (H+aza).
(E) Immunoblot analysis showing that glucose starvation (glucose) during hypoxia (H) reduces expression of DNMT1.
(F) Glucose starvation induces HIGD1A in hypoxic HeLa cells. H, hypoxia (1% O2)
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Figure 4. Expression of HIGD1A In Vivo and in Circulating Tumor Cells
(A) Pimonidazole and HIF-1a staining of MDA-MB 231 xenografts showing diminished expression of HIF-1a within perinecrotic regions where pimonidazole
staining is strongest.
(B) MDA-MB 231 xenografts showing enhanced expression of HIGD1A at perinecrotic regions where HIF-1a expression is diminished.
(C) Immunoblot analysis showing that expression of DNMT1 during hypoxia (H) versus hypoxia and glucose starvation (H –Glucose).
(D) Glucose starvation during hypoxia enhances HIGD1A protein level in MDA-MB 231 cells.
(E) Immunoblot analysis of HIGD1A expression in MDA-MB231 cells from which the xenografts where made, and in CTCs derived from the xenografts via blood
extraction, as a function of oxygen.
(F) Human primary glioblastoma biopsies demonstrate lack of HIGD1A induction in hypoxic regions where Ca9 induction is evident. Induction of HIGD1A is
evident only after treatment with the anti-angiogenesis agent bevacizumab.
N, normoxia (21% oxygen); H, hypoxia (1% oxygen); HBS, HIF binding site; HRE, hypoxia response element; CTC, circulating tumor cell.
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HIGD1A. One way that cells can survive metabolic stress is via
lowering cellular ROS and oxygen consumption, which are pa-
rameters associated with quiescence and dormancy-mediated
survival (Endo et al., 2014; Lagadinou et al., 2013; Lopes
et al., 2010). Consistent with this, we found that HIGD1A inter-
acts with the mitochondrial electron transport chain, modulates
oxygen consumption, ROS production, and AMPK activity to
promote cell survival during glucose starvation, while simulta-
neously suppressing tumor growth in vivo. Furthermore, anti-
VEGF therapy has previously been shown to induce AMPK
activity to promote tumor cell survival in vivo (Nardo et al.,
2011), which we also confirm to be associated with enhanced
HIGD1A activity in human GBM. Multiple studies have previ-
ously linked ROS suppression and cell survival with AMPK acti-
vation, likely via phosphatase inhibition (Davies et al., 1995;
Faubert et al., 2013; Han et al., 2010; Hofstetter et al., 2012; In-
draccolo, 2013; Ingebritsen et al., 1983; Jeon et al., 2012; Klaus
et al., 2012; Kwan et al., 2013; Rotte et al., 2010; Wu and Wei,
2012). Our studies confirm these observations and identify
HIGD1A as an important upstream component of this signaling
cascade. Furthermore, HIGD1A repression is associated with
tumor recurrence in breast cancers following therapy (Chanrion
et al., 2008), consistent with our observations that HIGD1A
expression helps repress tumor growth. These findings there-
fore provide novel insights into tumor cell adaptation mecha-
nisms to extreme environments and suggest that HIGD1A
may play an important role in tumor dormancy or recurrence
mechanisms (Giancotti, 2013).
The ability of HIGD1A expression to be regulated epigeneti-
cally provides an attractive model whereby environmental
factors can regulate HIGD1A expression independent of HIF
activity to modulate tumor growth. The gene encoding HIGD1A
is located on human chromosome 3p22.1, where many tumor
suppressors reside, andmany of which are inactivated via epige-
netic mechanisms (Bhat Singh and Amare Kadam, 2013; Buch-
hagen et al., 1994). Our analysis of the human Higd1a locus indi-
cated hypermethylation of the upstream promoter region in
various cancer cell lines that was able to bind HIF-1a but not
drive its hypoxic expression. This suggested that additional
pathways are required to induce HIGD1A in human cancers
in vivo, and we found that reducing the expression or activity
of DNAmethyl transferases (DNMTs) increased HIGD1A expres-
sion in vitro. This result is consistent with previous reports
linking DNMT1 inhibition with tumor suppressor reactivation in
response to environmental stressors in vivo (Xiang et al., 2014;
Yao et al., 2014; Lin et al., 2012). Constitutive basal expression
of HIGD1Amight be beneficial during growth permissive hypoxic
conditions without glucose deprivation. When glucose depriva-
tion becomes severe, enhanced HIGD1A expression modulated
by epigenetic mechanisms may help trigger a state of dormancy
and tumor growth inhibition (LaRue et al., 2004; Sutherland,
1988). Such dormant cells are typically resistant to many thera-
pies, enabling tumor cell survival and cancer recurrence (Indrac-
colo, 2013; Lin et al., 2012). Novel molecules are therefore being
developed to target these dormant cells (Zhang et al., 2014).
Small molecule modulators of the HIG family of mitochondrial
proteins (Lindert et al., 2014) may therefore prove useful in the
fight against cancer.CeEXPERIMENTAL PROCEDURES
Cell Culture
MEFs, HT1080, and HeLa cells were cultured in RPMI-1640, 10% FBS, and
110 mg/ml sodium pyruvate. Glucose starvation was achieved by using
glucose-free RPMI-1640. Normoxic cells were incubated at 5% CO2 and
21% O2 while hypoxia experiments were performed at 1% O2 with 5% CO2.
Oxygen Consumption and ROS Measurements
O2 consumption measured via use of the SeaHorse Extracellular Flux Analyzer
according to the manufacturer’s protocol. Mitochondrial ROS measured via
FACS-mediated analysis of Mito-Sox Red, and total ROS assayed by
measuring Cell-Rox Deep Red fluorescence via manufacturer’s instructions.
Immunohistochemistry
Formalin-fixed paraffin-embedded (FFPE) MEF and human tumor sections
were cut at 5 mm, subjected to antigen retrieval, treated with M.O.M. kit, and
incubated for 1 hr at 37C with primary antibody. Glioblastoma FFPE biopsies
were cut at 16-mm sections. Sections were incubated overnight at 4C in
primary antibody. A list of antibodies and suppliers is available in the Supple-
mental Information. Imaging was performed with a Zeiss Imager Z.2 fluores-
cence microscope equipped with an Apotome and axiovision-ZEN software
for optical sectioning and analysis.
Immunoprecipitation and Immunoblotting
GFP fusion proteins were immunoprecipitated with Chromotek-GFP-Trap
bead according to manufacturer’s recommendations. Pull-downs, as well as
all other immunoblotting, were performed via SDS-PAGE and blotted onto Im-
mobilon-FL membranes using semi-dry transfer. Membranes were blocked in
blocking buffer from LI-COR Biosciences and probed with primary antibodies
in LI-COR blocking buffer.
ChIP Assays
The ExactaCHIP kit was used for chromatin immunoprecipitation assays ac-
cording to the manufacturer’s protocol.
Tumor Models and Human Glioblastoma Samples
Tumor models and human glioblastoma samples are described in the Supple-
mental Experimental Procedures. All studies were approved by the UCSF
Committee on Human Research and Institutional Animal Care and Use
Committee.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and three figures and can be found with this article online at http://dx.doi.
org/10.1016/j.celrep.2015.01.020.
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